Do higher doses of carbimazole improve remission in Graves' disease?

QJM: An International Journal of Medicine

Volumn 89, Issue 5, 1996, Pages 381-385

  Wilson, R ^a,b   Buchanan, L ^a   Fraser, W D ^b   McKillop, J H ^a   Thomson, J A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; LIOTHYRONINE; THYROID HORMONE; THYROXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUTHYROIDISM; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; SIDE EFFECT;

EID: 0029973008     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/89.5.381     Document Type: Article

References (14)

1. Dunn JT. Choice of therapy in young adults with hyperthyroidism of Graves' disease. A brief case directed poll of 54 thyroidologists. Ann Int Med 1984; 100:819-21.
2. Medley AJ, Young R, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long term follow up of 434 patients. Clin Endocrinol 1989; 31:209-18.
3. Weetman AP, McGregor AM, Hall R. Evidence of an effect of antithyroid drugs on the natural history of Graves' disease. Clin Endocrinol 1984; 21:163-72.
4. Romaldini J, Bromberg N, Werner R, Tanaka LM, Rodrigues HF, Werener MC, Farah CS, Reis LC. Comparison of the effects of high and low dosage regimes of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57:563-70.
5. Reinwien D, Benker G, Lazarus JH, Alexander WD, and the European Multi Center Study Group on Antithyroid Drug Treatment. A proposed randomised trial of antithyroid drug dose in Graves' disease therapy. J Clin Endocrinol Metab 1993; 76:1516-21.
6. Wiberg JJ, Nuttall FQ. Methimazole toxicity from high doses. Ann Int Med 1972; 77:414-19.
7. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi, Miyamoto T, Arai M. Administration of thyroxine in the treatment of Graves' disease. N Engl J Med 1991; 324:947-90.
8. Tami M, Hayaki I, Kawaik K, Komaki G, Matsubayashi S, Kuma K, Kumaga LF, Nagataki S. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in Graves' disease patients. J Clin Endocrinol Metab 1995; 80:1481-4.
9. Allanic H, Faudet R, et al. Antithyroid drugs and Graves' disease. Aprospective randomised evaluation of the efficiency of treatment duration. J Clin Endocrinol Metab 1990; 70:675-9.
10. Weetman AP, Pickerill AP, Chatterjee VK, Edwards DM. Treatment of Graves' disease with the blocking replacement regime of antithyroid drugs; the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med 1994; 87:337-41.
11. Bing RF, Rosenthal FD. Early remission in thyrotoxicosis produced by short course of treatment. Acta Endocrinol 1982; 100:221-3.
12. Wilson R, McKillop JH, Pearson DW, Cuthbert GF, Thomson JA. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium - 99M uptake and serum thyroid stimulating hormone antibody levels. J Nucl Med 1985; 26:1024-8.
13. Weetman AP, Ratanachaiyavong S, et al. Prediction of outcome in Graves' disease after Carbimazole treatment. Q J Med 1986; 228:409-19.
14. Feldt-Rasmussen U, Sschleusener H, Caayon P. Meta analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission on the medical therapy of Graves' d isease. J Clin Endocrinol Metab 1994; 78:98-102.